Ocular manifestations of systemic lupus erythematosus

Rheumatology

Volumn 46, Issue 12, 2007, Pages 1757-1762

  Sivaraj, R R ^a   Durrani, O M ^a   Denniston, A K ^a   Murray, P I ^a   Gordon, Caroline ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Corneal; Lupus; Ocular; Ophthalmic; Optic; Retinal; Scleral

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ARTIFICIAL TEAR; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; EYE DROPS; HYDRALAZINE; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; PHOSPHOLIPID ANTIBODY; PREDNISOLONE; PROCAINAMIDE;

CHOROID DISEASE; CLINICAL FEATURE; CORNEA DISEASE; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DRY EYE; EPISCLERITIS; EYE BIOPSY; EYE DISEASE; EYE INFECTION; EYE PAIN; EYELID DISEASE; GLAUCOMA; HUMAN; IRIDOCYCLITIS; ISCHEMIC OPTIC NEUROPATHY; LACRIMAL GLAND DISEASE; LOW LEVEL LASER THERAPY; LUPUS ERYTHEMATOSUS; MEDICAL ASSESSMENT; MEDICAL SPECIALIST; OPHTHALMOLOGY; OPTIC NERVE DISEASE; OPTIC NEURITIS; ORBIT DISEASE; PRIORITY JOURNAL; PROGNOSIS; PROLIFERATIVE RETINOPATHY; RECOMMENDED DRUG DOSE; RETINA BLOOD VESSEL OCCLUSION; RETINOPATHY; REVIEW; SCLERA DISEASE; SCLERITIS; SLIT LAMP; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; VISUAL IMPAIRMENT; VISUAL SYSTEM EXAMINATION;

EYE DISEASES; FEMALE; HUMANS; KERATOCONJUNCTIVITIS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; OPHTHALMOSCOPY; OPTIC NEURITIS; PREVALENCE; PROGNOSIS; RETINAL ARTERY OCCLUSION; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; VISUAL ACUITY;

EID: 36448972714     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kem173     Document Type: Review

References (52)

1. Karpik AG, Schwartz MM, Dickey LE, Streaten BW, Roberts JL. Ocular immune reactants in patients dying with systemic lupus erythematosus. Clin Immunol Immunopathol 1985;35:295-312.
2. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for classification of systemic lupus arythematosus. Arthritis Rheum 1962;25:1271-7.
3. Isenberg DA, Rahman A, Allen E et al. BILAG 2004. Development and initial validation of an updated version of the British Islas Lupus Assessment Group's disease activity index for patients with systemic lupus arythematosus. Rheumatology 2005;44:902-6.
4. Nguyen QD, Foster CS. Systemic lupus erythematosus and the eye. Int Ophthalmol Clin 1998;38:33-60.
5. Peponis V, Kyttaris VC, Tyradellis C, Vergados I, Sitaras NM. Ocular manifestations of systemic lupus erythematosus: A clinical review. Lupus 2006;15:3-12.
6. Huey C, Jakobiec FA, Iwamoto T, Kennedy R, Farmer ER, Green WR. Discoid lupus erythematosus of the eyelids. Ophthalmology 1983;90:1389-98.
7. Jensen JL, Bergern HO, Gilboa IM, Husby G, Axell T. Oral and ocular sicca symptoms and findings are prevalent in systemic lupus erythematosus. Oral Pathol Med 1999;28:317-22.
8. Read RW. Clinical mini-review: Systemic lupus erythematosus and the eye. Ocul Immunol Inflamm 2004;12:87-99.
9. Norden D, Weinberg J, Schumacher HR, Keenan G, Freundlich B. Bilateral periorbital edema in systemic lupus erythematosus. J Immunol 1993;20:2158-60.
10. Jordan DR, McDonald H, Olberg B, McKim D, McKendry R. Orbital panniculitis as the initial manifestation of systemic lupus erythematosus. Ophthal Plast Rec; 1993;9:71-5.
11. Stavrou P, Murray PI, Batta K, Gordon C. Acute ocular ischemia and orbital inflammation associated with systemic lupus erythematosus. Br J Ophthalmol 2002;86:474-6.
12. Grimson BS, Simons KB. Orbital inflammation, myositis and systemic lupus erythematosus. Arthritis Rheum 1983;101:736-8.
13. Foster CS. Ocular surface manifestations of neurological and systemic disease. Int Ophthalmol Clin 1979;19:207-42.
14. Messmer EM, Foster CS. Vasculitic peripheral ulcerative karatitis. Surv Ophthalmol 1999;43:379-96.
15. Foster CS. Immunosuppressive therapy for external ocular inflammatory disease. Ophthalmology 1980;87:140-50.
16. Hakin KN, Watson PG. Systemic associations of scleritis. Int Ophthalmol Clin 1991;31:111-29.
17. Gold DH, Morris DA, Henkind P. Ocular findings in systemic lupus erythematosus. Br J Ophthalmol 1972;56:800-4.
18. Arevalo JF, Lowder CY, Muci-Mendoza R. Ocular manifestations of systemic lupus erythemalosus. Curr Opin Ophthalmol 2002;13:404-10.
19. Durrani OM, Gordon C, Murray PI. Primary anti-phospholipid antibody syndrome (APS): Current concepts. Surv Ophthalmol 2002;47:215-38.
20. Coppeto J, Lessel S. Retinopathy in systemic lupus arythematosus. Arch Ophalmol 1977;95:794-7.
21. Jabs DA, Fine SL, Hochberg MC, Newman SA, Heiner GG, Stevens MB. Severe retinal vaso-occlusive disease in systemic lupus erythematosus. Arch Ophalmol 1986;104:558-63.
22. Hall S, Buettner H, Luthra HS. Occlusive retinal vascular disease in systemic lupus erythematosus. J Rheumatol 1984;11:846-50.
23. Giorgi D, Pace F, Giorgi A, Bonomo L, Gabrieli CB. Retinopathy in systemic lupus erythematosus: Pathogenesis and approach to therapy. Hum Immunol 1999;60:688-96.
24. Wisotsky BJ, Magat-Gordon CB, Puklin JE. Angle closure glaucoma as an initial presentation of systemic lupus erythematosus. Ophthalmology 1998;105:1170-2.
25. Laviña AM, Agarwal A, Hunyor A, Gass JD. Lupus choroidopathy and choroidal effusions. Retina 2002;22:643-47.
26. Yap EY, Fam HB, Leong KP, Buettner H. Nocardia choroidal abscess in a patient with systemic lupus erythemalosus. Aust N Z J Ophthalmol 1998;26:337-8.
27. Wang JC, Chuah GC, Yap EY. Tuberculous choroidal granulomas in a patent with systemic lupus arythematosus. Int Ophthalmol 2001;24:107-9.
28. Cunningham ET Jr, Alfred ER, Irvine AR. Central serous chorioretinopethy in patients with systemic lupus arythematosus. Ophthalmology 1996;103:2081-90.
29. Chan WM, Li EK, Chan AY, Lam DS. Bilateral retinal detachment in a young woman. Lancet 2003;361:2044.
30. Hochberg MC, Boyd RE, Aheam JM et al. Systemic lupus erythematosus: A review of clinico-laboratory features and immunogenetic markers in 150 patients with emphasis on demographic subsets. Medicine 1985;64;285-96.
31. Feinglass EJ, Arnett FC, Dorsch CA, Zizic TM, Stevens MB. Neuropsychiatric manifestations of systemic lupus erythematosus: diagnosis, clinical spectrum and relationship to other features of the disease. Medicine 1976;55:323-39.
32. Jabs DA, Miller NR, Newman SA, Johnson MA, Stevens MB. Optic neuropathy in systemic lupus erythematosus. Arch Opthhalmol 1986;104:564-8.
33. Cinefro RJ, Frenkel M. Systemic lupus erythematosus presenting as optic neuritis. Ann Ophthalmol 1978;10:559-63.
34. Ahmadieh H, Roodpayma S, Azarmina M, Soheilian M, Sajjadi SH. Bilateral simultaneous optic neuritis in childhood systemic lupus erythematosus. A case report. J Neuroophthalmol 1994;14:84-6.
35. Allen IV, Millar JH, Kirk J, Shillington RK. Systemic lupus erythematosus clinically resembling multiple sclerosis and with unusual pathological and ultrastructural features. J Neurol Neurosurg Psychiatry 1979;42:392-401.
36. Giorgi D, Balacco Gabrieli C. Optic neuropathy in systemic lupus erythematosus and antiphospholipid syndrome (APS): Clinical features, pathogenesis, review of literature and proposed ophthalmological criteria for APS diagnosis. Clin Rheumatol 1999;18:124-31.
37. Keane J. Eye movement abnormalities in systemic lupus erythematosus. Arch Neurol 1995;52:1145-9.
38. Galindo M, Pablos JL, Gomez-Reino JJ. Intemuclear ophthalmoplegia in systemic lupus erythematosus. Samin Arthritis Rheum 1998;28:179-86.
39. Jackson G, Miller M, Littlejohn G, Helme R, King R. Bilateral internuclear ophthalmoplegia in systemic lupus erythematosus. J Rheumatol 1986;13:1161-2.
40. Yigit A, Bingol A, Mutluer N, Tascilar N. The one-and-a-half syndrome in systemic lupus arythematosus. J Neuroophthalmol 1996;16:274-6.
41. Bingisser R, Speich R, Fontana A, Gmur J, Vogel B, Landis T. Lupus erythematosus and Miller-Fisher syndrome. Arch Neurol 1994,51:828-30.
42. Donders RC, Kapelle LJ, Derksen RH et al. Transient monocular blindness and antiphospholipid antibodies in systemic lupus erythematosus. Neurology 1998;51:535-40.
43. DelGiudice GC, Scher CA, Athreya BH, Diamond GR. Pseudotumor cerebri and childhood systemic lupus erythematosus. J Rheumatol 1986;13:748-52.
44. Carlow TJ, Glaser JS. Pseudotumor cerebri syndrome in systemic lupus orythematosus. JAMA 1974;220:197-200.
45. Ravelli A, Di Fuccia G, Caporali R, Malvezzi F, Montecucco C, Martini A. Severe retinopathy in systemic lupus erythematosus associated with IgG anticardiolipin antibodies. Acta Paediatr 1993;82:624-6.
46. Asherson RA, Merry P, Acheson JF, Harris EN, Hughes GR. Antiphospholipid antibodies: A risk factor for occlusive ocular vascular disease in systemic lupus erythematosus and the 'primary' antiphospholipid syndrome. Ann Rheum Dis 1989;48:358-61.
47. Chen YC, Chong TT, Lai MH, Wu CH. Overwhelming septic cavemous sinus thrombosis in a woman after combination of high-dose steroid and intravenous cyclophosphamide therapy for lupus nephritis. Lupus 2000;9:78-9.
48. Hobbs HE, Sorsby A, Freedman A. Retinopathy following chloroquine therapy. Lancet 1959;2:478-80.
49. Buckley R, Graham E, Jones S, Silman A, Tullo A. Ocular toxicity and hydroxychloroquine: Guidelines for screening 2004. www.rcophth.ac.uk/ docs/publications/oculartoxicity2004.pdf
50. Marmor MF, Carr RE, Easterbrook M et al. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy. A report by the American Academy of Ophthalmology. Ophthalmology 2002;109:1377-82.
51. Mavrikakis I, Sfikakis PP, Mavrikakis E et al. The incidence of irresversible retinal toxicity in patients treated with hydroxychloroquine; a reappraisal. Ophthalmology 2003;110:1321-6.
52. Lee AG. Hydroxychloroquine screening. Br J Ophthalmol 2005;89:521-2.